Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.

[1]  F. Sheehan,et al.  [The thrombolysis treatment of acute myocardial infarct at the site of the emergency. A randomized double-blind study]. , 2008, Deutsche medizinische Wochenschrift.

[2]  Kenneth F Schulz,et al.  Blinding in randomised trials: hiding who got what , 2002, The Lancet.

[3]  R. Califf,et al.  Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. , 2001 .

[4]  J. Wardlaw.  Overview of Cochrane thrombolysis meta-analysis , 2001, Neurology.

[5]  Assent investigators.  Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction , 2001, The Lancet.

[6]  K. Coyne,et al.  A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial. , 2001, American heart journal.

[7]  E. Antman,et al.  Bolus fibrinolytic therapy in acute myocardial infarction. , 2001, JAMA.

[8]  R. Califf,et al.  Predictors of left ventricular function after acute myocardial infarction: effects of time to treatment, patency, and body mass index: the GUSTO-I angiographic experience. , 2001, American heart journal.

[9]  P. Armstrong,et al.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. , 2001 .

[10]  D. Collen,et al.  Intracranial haemorrhage with bolus thrombolytic agents , 2000, The Lancet.

[11]  J. Pell,et al.  Trends in case-fatality in 117 718 patients admitted with acute myocardial infarction in Scotland. , 2000, European heart journal.

[12]  A. Skene,et al.  Survival Outcomes 1 Year After Reperfusion Therapy With Either Alteplase or Reteplase for Acute Myocardial Infarction: Results From the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial , 2000, Circulation.

[13]  R. Califf,et al.  Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from canada and the united states. The North American GUSTO-I and GUSTO-III investigators. , 2000, The Canadian journal of cardiology.

[14]  R. Califf,et al.  Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). , 2000, The American journal of cardiology.

[15]  L. Morrison,et al.  Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. , 2000, JAMA.

[16]  K. Lee,et al.  Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. , 2000, Circulation.

[17]  E. Shacter,et al.  Clinical trial (GUSTO-1 and INJECT) evidence of earlier death for men than women after acute myocardial infarction. , 2000, The American journal of cardiology.

[18]  R. Califf,et al.  Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. , 1999, Journal of the American College of Cardiology.

[19]  F. Verheugt,et al.  Effect of prehospital thrombolysis on aborting acute myocardial infarction. , 1999, The American journal of cardiology.

[20]  F. Werf.  Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.

[21]  D A Sandler,et al.  Call to needle times after acute myocardial infarction , 1999, BMJ.

[22]  E. Braunwald,et al.  Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. , 1999, American heart journal.

[23]  D. Massel.  Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase. , 1999, The Canadian journal of cardiology.

[24]  R. Giugliano,et al.  TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. , 1998, Circulation.

[25]  F. Werf.  A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial Infarction , 1998 .

[26]  E. Topol.  A comparison of reteplase with alteplase for acute myocardial infarction. , 1998, The New England journal of medicine.

[27]  S. J. Park.  Comparison of double bolus urokinase versus front-loaded alteplase regimen for acute myocardial infarction. Thrombolysis in Myocardial Infarction in Korea (TIMIKO) study group. , 1998, The American journal of cardiology.

[28]  R. Califf,et al.  Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. , 1998, Journal of the American College of Cardiology.

[29]  K. Stringer.  TIMI Grade Flow, Mortality, and the GUSTO‐III Trial , 1998, Pharmacotherapy.

[30]  J S Martin,et al.  Utility of the prehospital electrocardiogram in diagnosing acute coronary syndromes: the Myocardial Infarction Triage and Intervention (MITI) Project. , 1998, Journal of the American College of Cardiology.

[31]  E. Topol,et al.  Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. , 1998, Journal of the American College of Cardiology.

[32]  K. Lee,et al.  Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries. , 1998, The American journal of cardiology.

[33]  R. Califf,et al.  Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. , 1998, Circulation.

[34]  R. Califf,et al.  Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. , 1998, Journal of the American College of Cardiology.

[35]  R. Califf,et al.  Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. , 1998, Stroke.

[36]  R. Califf,et al.  Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. , 1998, Journal of the American College of Cardiology.

[37]  R. Califf,et al.  Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators. , 1998, Circulation.

[38]  David P Miller,et al.  Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries. , 1998, The American journal of cardiology.

[39]  M. Weinstein,et al.  Economic Evaluation Alongside Multinational Clinical Trials: Study Considerations for GUSTO iib , 1997, International Journal of Technology Assessment in Health Care.

[40]  R. Califf,et al.  Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. , 1997, Journal of the American College of Cardiology.

[41]  J. Rawles.  Myocardial salvage with early anistreplase treatment , 1997, Clinical cardiology.

[42]  D. Hu,et al.  Multicenter clinical trial of thrombolytic therapy in 1,406 patients with acute myocardial infarction. Collaborative Group of Clinical Trial for Urokinase Therapy. , 1997, Chinese medical journal.

[43]  J. Rawles,et al.  Quantification of the benefit of earlier thrombolytic therapy: five-year results of the Grampian Region Early Anistreplase Trial (GREAT). , 1997, Journal of the American College of Cardiology.

[44]  K. Newby,et al.  Clinical outcomes according to time to treatment , 1997, Clinical cardiology.

[45]  J. Birkhead.  Thrombolytic treatment for myocardial infarction: an examination of practice in 39 United Kingdom hospitals. Myocardial Infarction Audit Group. , 1997, Heart.

[46]  R. Califf,et al.  Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. , 1997, Journal of the American College of Cardiology.

[47]  R. Califf,et al.  Incidence and Predictors of Bleeding After Contemporary Thrombolytic Therapy for Myocardial Infarction , 1997 .

[48]  David P Miller,et al.  Long-Term Follow-Up of Gender-Specific Outcomes After Thrombolytic Therapy for Acute Myocardial Infarction from the GUSTO-I Trial , 1997 .

[49]  R. Califf,et al.  Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial , 1997 .

[50]  W. Klein,et al.  Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction. , 1997, The American journal of cardiology.

[51]  R. Califf,et al.  Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. , 1997, Journal of the American College of Cardiology.

[52]  Luke Vale,et al.  An economic evaluation of thrombolysis in a remote rural community , 1997, BMJ.

[53]  C. Naylor,et al.  Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[54]  M. Haugh,et al.  Pre-hospital and hospital time delays in thrombolytic treatment in patients with suspected acute myocardial infarction. Analysis of data from the EMIP study. European Myocardial Infarction Project. , 1997, European heart journal.

[55]  R. Perry,et al.  Transluminal extraction atherectomy for stent restenosis in a saphenous vein bypass graft. , 1997, European heart journal.

[56]  R. Wilcox.  Clinical trials in thrombolytic therapy: what do they tell us? INJECT 6-month outcomes data. , 1996, The American journal of cardiology.

[57]  R. Califf,et al.  Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. , 1996, The American journal of cardiology.

[58]  R. Califf,et al.  Relation of Increased Arterial Blood Pressure to Mortality and Stroke in the Context of Contemporary Thrombolytic Therapy for Acute Myocardial Infarction , 1996, Annals of Internal Medicine.

[59]  M. Lu,et al.  A comparative study of intravenous accelerated streptokinase dose regimen with conventional dose regimen for coronary thrombolysis. , 1996, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[60]  F. Van de Werf,et al.  Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. GUSTO-1 Angiographic Investigators. , 1996, Circulation.

[61]  K. Lee,et al.  Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. , 1996, Circulation.

[62]  Eric Boersma,et al.  Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour , 1996, The Lancet.

[63]  R. Califf,et al.  One-Year Results From the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) Trial , 1996 .

[64]  W. Weaver,et al.  Influence of early prehospital thrombolysis on mortality and event-free survival (the Myocardial Infarction Triage and Intervention [MITI] Randomized Trial). MITI Project Investigators. , 1996, The American journal of cardiology.

[65]  J R Hampton,et al.  Mega-trials and equivalence trials: experience from the INJECT study. , 1996, European heart journal.

[66]  W. Weaver,et al.  Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. , 1996, Circulation.

[67]  R. Califf,et al.  Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: the GUSTO-I angiographic experience. , 1996, Journal of the American College of Cardiology.

[68]  H. Friedman,et al.  Streptokinase versus Alteplase in Acute Myocardial Infarction , 1996, Journal of the Royal Society of Medicine.

[69]  A. Maggioni,et al.  Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era. The GISSI-2 results. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico. , 1996, Circulation.

[70]  J A Lewis,et al.  Trials to assess equivalence: the importance of rigorous methods , 1996, BMJ.

[71]  F Van de Werf,et al.  Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. , 1996, Journal of the American College of Cardiology.

[72]  R. Califf,et al.  Comparisons of Characteristics and Outcomes Among Women and Men With Acute Myocardial Infarction Treated With Thrombolytic Therapy , 1996 .

[73]  K. Lee,et al.  Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. , 1996, Circulation.

[74]  M. Pfisterer,et al.  Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy. , 1996, European heart journal.

[75]  J. Rawles,et al.  Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT) , 1996, BMJ.

[76]  J. Deckers,et al.  Pre-hospital thrombolytic therapy with either alteplase or streptokinase. Practical applications, complications and long-term results in 529 patients. , 1995, European heart journal.

[77]  K Wegscheider,et al.  Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. , 1995, Journal of the American College of Cardiology.

[78]  R. Califf,et al.  Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. , 1995, Journal of the American College of Cardiology.

[79]  R. Califf,et al.  Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. , 1995, Circulation.

[80]  K. Goa,et al.  Alteplase , 1995, PharmacoEconomics.

[81]  Rose Ea.  Is the use of t-PA as compared with streptokinase cost effective? , 1995 .

[82]  J. Kellett,et al.  Comparison of "Accelerated" Tissue Plasminogen Activator with Streptokinase for Treatment of Suspected Myocardial Infarction , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.

[83]  E R Bates,et al.  Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. , 1995, Journal of the American College of Cardiology.

[84]  J. Boissel.  The European Myocardial Infarction Project: an assessment of pre-hospital thrombolysis. , 1995, International journal of cardiology.

[85]  R. Califf,et al.  Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. , 1995, European heart journal.

[86]  D. Chamberlain,et al.  Delay times in the administration of thrombolytic therapy: the Brighton experience. , 1995, International journal of cardiology.

[87]  R. Wilcox,et al.  Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence International Joint Efficacy Comparison of Thrombolytics , 1995, The Lancet.

[88]  J. Kalbfleisch,et al.  More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators. , 1995, Circulation.

[89]  W. Weaver,et al.  Time to thrombolytic treatment: factors affecting delay and their influence on outcome. , 1995, Journal of the American College of Cardiology.

[90]  R. Califf,et al.  Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. , 1995, Journal of the American College of Cardiology.

[91]  C. Cannon,et al.  Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. , 1995, Journal of the American College of Cardiology.

[92]  R. Diaz,et al.  Acute myocardial infarction in the young--the role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. , 1995, European heart journal.

[93]  C. Cannon,et al.  Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. , 1994, Journal of the American College of Cardiology.

[94]  R. Califf,et al.  Mortality Within 24 Hours of Thrombolysis for Myocardial Infarction: The Importance of Early Reperfusion , 1994, Circulation.

[95]  P. Glasziou,et al.  Quality of life six months after myocardial infarction treated with thrombolytic therapy , 1994, The Medical journal of Australia.

[96]  A. Maggioni,et al.  A simple electrocardiographic predictor of the outcome of patients with acute myocardial infarction treated with a thrombolytic agent. A Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2)-Derived Analysis. , 1994, Journal of the American College of Cardiology.

[97]  R. Califf,et al.  More on the GUSTO trial. , 1994, The New England journal of medicine.

[98]  J. Rawles,et al.  Electrocardiographic evidence of reperfusion occurring before hospital admission. A Grampian Region Early Anistreplase Trial (GREAT) sub-study. , 1994, European heart journal.

[99]  R. Califf,et al.  Holding GUSTO Up to the Light , 1994, Annals of Internal Medicine.

[100]  P. Aylward.  The GUSTO Trail: background and baseline characteristics , 1993 .

[101]  F. Werf.  Mortality results in GUSTO , 1993 .

[102]  R. Diaz,et al.  After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptoki , 1993, Circulation.

[103]  R. Schröder,et al.  Prehospital thrombolysis: beneficial effects of very early treatment on infarct size and left ventricular function. , 1993, Journal of the American College of Cardiology.

[104]  J. Rawles,et al.  Loss of quality adjusted days as a trial endpoint: effect of early thrombolytic treatment in suspected myocardial infarction. Grampion Region Early Anistreplase Trial (GREAT). , 1993, Journal of epidemiology and community health.

[105]  P. Ridker,et al.  Large-Scale Trials of Thrombolytic Therapy for Acute Myocardial Infarction: GISSI-2, ISIS-3, and GUSTO-1 , 1993, Annals of Internal Medicine.

[106]  P. Kudenchuk,et al.  Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. , 1993, JAMA.

[107]  J. Rawles.  Recovery of left ventricular function after acute myocardial infarction: efficacy of domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial , 1993, Coronary artery disease.

[108]  F. Sheehan,et al.  Effect of thrombolysis on acute mitral regurgitation during evolving myocardial infarction. Experience from the Thrombolysis in Myocardial Infarction (TIMI) Trial. , 1993, Journal of the American College of Cardiology.

[109]  E. Negri,et al.  Determinants of 6‐Month Mortality in Survivors of Myocardial Infarction After Thrombolysis Results of the GISSI‐2 Data Base , 1993, Circulation.

[110]  V. Goel,et al.  Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction. , 1993, The Canadian journal of cardiology.

[111]  V. Rasmussen,et al.  The prevalence of myocardial ischemia six months after thrombolytic treatment of acute coronary episodes. A subset of a placebo controlled, randomised trial, the ASSET Study. , 1993, International journal of cardiology.

[112]  R. Collins,et al.  ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials. , 1993, The American journal of cardiology.

[113]  L. Becker,et al.  TIMI Perfusion Grade 3 but Not Grade 2 Results in Improved Outcome After Thrombolysis for Myocardial Infarction Ventriculographic, Enzymatic, Electrocardiographic Evidence From the TEAM‐3 Study , 1993, Circulation.

[114]  M. Schaller,et al.  Comparison of results of intravenous infusion of anistreplase versus streptokinase in acute myocardial infarction. , 1993, The American journal of cardiology.

[115]  H. White,et al.  Comparative case fatality analysis of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial: variation by country beyond predictive profile. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. , 1993, Journal of the American College of Cardiology.

[116]  L. Becker,et al.  Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators. , 1992, Journal of the American College of Cardiology.

[117]  J. R. Williams,et al.  Prehospital thrombolysis in a rural community: Short- and long-term survival , 1992, Cardiovascular Drugs and Therapy.

[118]  F. Van de Werf,et al.  The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. , 1992, The New England journal of medicine.

[119]  M. Simoons,et al.  Prehospital thrombolysis with alteplase (rt-PA) in acute myocardial infarction. , 1992, European heart journal.

[120]  I. Ovsyshcher,et al.  Short- and Long-Term Comparative Study of Anistreplase Versus Streptokinase in Acute Myocardial Infarction , 1992, Angiology.

[121]  C. P. Lee,et al.  A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction. , 1992, American heart journal.

[122]  U. Tebbe,et al.  Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS) , 1992, Journal of the American College of Cardiology.

[123]  David Hunt,et al.  ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION , 1992 .

[124]  Andrew M. Muckle.  Prehospital thrombolysis in acute myocardial infarction: the Belgian eminase prehospital study (BEPS). BEPS Collaborative Group. , 1992, European heart journal.

[125]  K. Fox,et al.  Effect of "fast track" admission for acute myocardial infarction on delay to thrombolysis. , 1992, BMJ.

[126]  J. Anderson,et al.  Effects of early thrombolytic therapy (anistreplase versus streptokinase) on enzymatic and electrocardiographic infarct size in acute myocardial infarction. TEAM-2 Investigators. , 1991, The American journal of cardiology.

[127]  J. Maublant,et al.  Comparative Effects of APSAC and rt‐PA on Infarct Size and Left Ventricular Function in Acute Myocardial Infarction: A Multicenter Randomized Study , 1991, Circulation.

[128]  A. Maggioni,et al.  Cerebrovascular events after myocardial infarction: analysis of the GISSI trial. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). , 1991, BMJ.

[129]  J. Gore,et al.  Early tPA treatment and aeromedical transport of patients with acute myocardial infarction. , 1991, Journal of interventional cardiology.

[130]  H. White,et al.  Comparison of the effects of streptokinase and tissue plasminogen activator on regional wall motion after first myocardial infarction: analysis by the centerline method with correction for area at risk. , 1991, Journal of the American College of Cardiology.

[131]  S. Kimata,et al.  Intravenous recombinant tissue-type plasminogen activator (rt-PA) and urokinase (UK) in patients with evolving myocardial infarction--a multicenter double-blind, randomized trial in Japan. , 1991, Japanese circulation journal.

[132]  A. Cribier,et al.  Invasive reperfusion study. II. Multicentre European randomized trial of anistreplase vs streptokinase in acute myocardial infarction. , 1991, European heart journal.

[133]  Jeffrey L. Anderson,et al.  MulticenterPatency Trial ofIntravenous Anistreplase ComparedWith Streptokinase in AcuteMyocardial Infarction , 1991, Circulation.

[134]  F. Sheehan,et al.  Prehospital thrombolysis in acute myocardial infarction. , 1990, The American journal of cardiology.

[135]  S. Yusuf,et al.  Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction. , 1990, Circulation.

[136]  H. Hod,et al.  Improved survival but not left ventricular function with early and prehospital treatment with tissue plasminogen activator in acute myocardial infarction. , 1990, The American journal of cardiology.

[137]  A. Maggioni,et al.  The GISSI-2 trial: premises, results, epidemiological (and other) implications. Gruppo Italiano per lo Studio delia Sopravvivenza nell'Infarto Miocardico. , 1990, Clinical cardiology.

[138]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.

[139]  H. Hod,et al.  Should thrombolytic therapy be administered in the mobile intensive care unit in patients with evolving myocardial infarction? A pilot study. , 1990, Journal of the American College of Cardiology.

[140]  P. Dunselman,et al.  A double-blind randomized multicenter dose-ranging trial of intravenous streptokinase in acute myocardial infarction. , 1990, The American journal of cardiology.

[141]  A. Castaigne,et al.  Prehospital use of APSAC: results of a placebo-controlled study. , 1989, The American journal of cardiology.

[142]  C. Wilson,et al.  A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction. , 1989, British heart journal.

[143]  H. White,et al.  Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. , 1989, The New England journal of medicine.

[144]  E. Braunwald,et al.  Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. , 1988, The American journal of cardiology.

[145]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[146]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[147]  F H Sheehan,et al.  The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. , 1987, Circulation.

[148]  R. W. Brower,et al.  RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.

[149]  M. Bala,et al.  Time to Treatment and Cost of Thrombolysis: A Multicenter Comparison of tPA and rPA , 2004, Journal of Thrombosis and Thrombolysis.

[150]  P. Armstrong,et al.  Single-bolus tenecteplase and front-loaded alteplase remain equivalent afte rone year: follow-up results of the ASSENT-2 trial , 2000 .

[151]  W. Shen,et al.  A comparative study on the effects of low dose of tPA and different regimens of intravenous urokinase in acute myocardial infarction. , 1999, Chinese medical journal.

[152]  R. Califf,et al.  Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase Results from GUSTO-III , 1999 .

[153]  R. Califf,et al.  Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries. , 1998, Journal of the American College of Cardiology.

[154]  E. Braunwald,et al.  TNK-tissue plasminogen activator compared with front-loaded tissue plasminogen activator in acute myocardial infarction: primary results of the TIMI 10B trial , 1997 .

[155]  J. Kellett.  COST-EFFECTIVENESS OF ACCELERATED TISSUE PLASMINOGEN ACTIVATOR FOR ACUTE MYOCARDIAL INFARCTION , 1996 .

[156]  J. Anderson,et al.  Relation of reperfusion success with anistreplase or alteplase in acute myocardial infarction to body weight. The TEAM-3 investigators. , 1994, The American journal of cardiology.

[157]  J. Rawles.  Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). , 1994, Journal of the American College of Cardiology.

[158]  J. Bassand.  GUSTO (Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries): logic wins at last. , 1994, European heart journal.

[159]  K. Swedberg,et al.  Early electrocardiographic changes in acute myocardial infarction treated by streptokinase or alteplase: a randomized study with dynamic, multi-lead, electrocardiographic monitoring. , 1993, Cardiology.

[160]  M. Krucoff,et al.  Global utilization of streptokinase and tPA for occluded arteries (GUSTO) ECG-monitoring substudy. Study design and technical considerations. , 1993, Journal of electrocardiology.

[161]  V. Goel,et al.  Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction. , 1992, The Canadian journal of cardiology.

[162]  W. Gibler,et al.  PREHOSPITAL DIAGNOSIS AND TREATMENT OF ACUTE MYOCARDIAL INFARCTION : A NORTH-SOUTH PERSPECTIVE , 1991 .

[163]  K. Swedberg,et al.  Prehospital thrombolysis in suspected acute myocardial infarction: results from the TEAHAT Study. , 1991, Journal of internal medicine. Supplement.

[164]  H. White,et al.  Left ventricular function as an end-point of thrombolytic therapy. , 1990, European heart journal.

[165]  B. Magnani,et al.  Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. , 1989, Journal of the American College of Cardiology.

[166]  R. Luepker,et al.  Trends in coronary heart disease mortality : the influence of medical care , 1988 .

[167]  M. Gottwik,et al.  Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). , 1988, Journal of the American College of Cardiology.

[168]  A. Jaffe,et al.  Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .

[169]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.